Beneficial effect of infliximab on refractory sarcoidosis

Danish Medical Journal

Volumn 59, Issue 12, 2012, Pages

  Ørum, Matilde ^a   Hilberg, Ole ^b   Krag, Susanne ^b   Bendstrup, Elisabeth ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE; INFLIXIMAB; INTERLEUKIN 2; METHOTREXATE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SARCOIDOSIS; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

EID: 84873197840     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J 1999;14:735-7.
2. Rossman MD, Newman LS, Baughman RP et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:201-8.
3. Van den Brande JMH, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterolo-gy 2003;124:1774-85.
4. Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sar-coidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802.
5. Sweiss NJ, Welsch MJ, Curran JJ et al. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 2005;53:788-91.
6. Pritchard C, Nadarajah K. Tumor necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004;63:318-20.
7. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4.
8. Keijsers RGM, Verzijlbergen JF, van Diepen DM et al. F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008;25:143-50.
9. Milman N, Graudal N, Loft A et al. Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 2012;DOI:10.1111/j.1752-699X.2011.00276.x.
10. Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti-TNF-alpha therapy in patients with chron-ic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 2008;225:457-61.
11. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005;43:7-11.
12. Cruz BA, Reis DD, Araujo CA. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int 2007;27:1181-3.
13. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71.
14. Lindstedt EW, Baarsma GS, Kuijpers RW et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533-6.
15. Kiorpelidou D, Gaitanis G, Zioga A et al. Short course of infliximab for disfiguring lupus pernio. Eur J Dermatol. 2008;18:727-9.
16. Stagaki E, Mountford WK, Lackland DT et al. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009;135:468-76.
17. Lahmer T, Knopf A, Lanzl I et al. Using TNF-alpha antagonist Adalimumab for treatment for multisystem sarcoidosis: a case study. Rheumatol Int 2012;32:2367-70.
18. Field S, Regan AO, Sheahan K et al. Recalcitrant cutaneous sarcoidosis responding to ada-limumab but not to etanercept. Clin Exp Dermatol 2010;35:795-6.
19. Denys BG, Bogaerts Y, Coenegrachts KL et al. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clin Sci (Lond) 2007;112:281-9.
20. Erckens RJ, Mostard RL, Wijnen PA et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012;250:713-20.